ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Comparative in vitro analysis of sulbactam-durlobactam against extensively drug resistant (XDR) and non-XDR carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates collected from a tertiary care facility in North India.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ConsistentAntimicrobial agents and chemotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the in vitro activity of sulbactam-durlobactam (SUL-DUR), a novel β-lactam/β-lactamase inhibitor combination, against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates from a tertiary care facility in north India. Special focus was placed on extensively drug-resistant (XDR) strains, a subgroup which is likely to be underrepresented in global surveillance.A total of 100 non-duplicate CRAB clinical isolates were included in the study. Isolates were obtained from various clinical specimens, primarily respiratory samples, and characterized using MALDI-TOF MS. Susceptibility testing for SUL-DUR was performed using both broth microdilution (BMD) and disk diffusion (DD) in accordance with CLSI M100, 35th edition guidelines. Quality control was ensured using A. baumannii NCTC 13304 strain. Descriptive analysis and categorical interpretations were employed to evaluate susceptibility patterns. Of the 100 CRAB isolates, 80% were classified as XDR. Overall, 52% of isolates were susceptible to SUL-DUR, 46% resistant, and 2% intermediate. Among XDR strains, susceptibility dropped to 40%. Respiratory isolates, particularly from endotracheal aspirates and bronchoalveolar lavage, exhibited higher resistance rates. All non-XDR isolates (n=20) were susceptible to SUL-DUR. BMD and DD methods showed 100% categorical agreement. The MIC distribution ranged from≤0.25 to ≥128 µg/mL.SUL-DUR showed promising in vitro activity against CRAB, but with reduced efficacy in XDR strains, particularly respiratory isolates. High concordance between BMD and DD supports the utility of disk diffusion in resource-limited settings.
Indexed as
Identifiers
41165941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.